By Scientia Professor Gregory John Dore

Conference Abstracts

Martinello M; Bhagani S; Gane EJ; Orkin C; Cooke G; Kulasegaram R; Shaw D; Hellard M; Tu E; Filep E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews G, 2017, 'Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: The TARGET3D Study', in HEPATOLOGY, WILEY, DC, Washington, Vol. 66, pp. 574A - 575A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017

Foster GR; Grebely J; Sherman KE; Wang S; Dore GJ; Baumgarten A; Conway B; Jackson DF; Asselah T; Gschwantler M; Tomasiewicz K; Aguilar HI; Alami NN; Dumas EO; Hu Y; Mensa FJ, 2017, 'Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1-6 and Recent Drug Use', in HEPATOLOGY, WILEY, DC, Washington, Vol. 66, pp. 636A - 637A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000412089801323&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop AJ; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer CM; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2017, 'Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S513 - S513, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017

Foster GR; Gane E; Asatryan A; Asselah T; Ruane PJ; Pol S; Poordad F; Stedman CA; Dore G; Roberts SK; Kaita K; Vierling J; Vargas HE; Kort J; Lin C-W; Liu R; Ng T; Mensa F, 2017, 'ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naive HCV genotype 3-infected patients without cirrhosis', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S33 - S33, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30326-4

Marshall AD; Nielsen S; Cunningham EB; Aghemo A; Alho H; Backmund M; Bruggmann P; Dalgard O; Flisiak R; Foster G; Gheorghe L; Goldberg D; Goulis I; Hickman M; Hoffmann P; Jancoriene L; Jarcuska P; Kaberg M; Makara M; Maimets M; Marinho R; Maticic M; Norris S; Olafsson S; Ovrehus A; Pawlotsky J-M; Pocock J; Robaeys G; Roncero C; Simonova M; Sperl J; Tait M; Tolmane I; Tomaselli S; van der Valk M; Vince A; Dore GJ; Lazarus JV; Grebely J, 2017, 'Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe', in JOURNAL OF HEPATOLOGY, ELSEVIER, NETHERLANDS, Amsterdam, Vol. 66, pp. S95 - S96, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver-Disease, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30450-6

Martinello M; Dore GJ; Bopage RI; Finlayson R; Baker D; Bloch M; Wilcox A; Filep E; Hellard M; Matthews GV, 2017, 'DAA treatment scale-up in HIV/HCV co-infection: characterisinga population at risk for reinfection', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S495 - S496, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31388-0

Lamoury FM; Hajarizadeh B; Soker A; Martinez D; Quek C; Cunningham P; Catlett B; Cloherty GA; Marks P; Amin J; Grebely J; Dore GJ; Applegate TL, 2017, 'Hepatitis C virus core antigen and dried blood spots as simplified hepatitis C virus diagnostic tools', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S710 - S710, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31901-3

Grebely J; Jacobson IM; Kayali Z; Verna EC; Shiffman ML; Hyland RH; Stamm LM; Huang KC; Brainard DM; McHutchison JG; Pol S; Chung RT; Bernstein DE; Dore G, 2017, 'SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S513 - S514, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401056601272&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Bartlett SR; Grebely J; Eltahla AA; Reeves JD; Howe A; Miller V; Bull RA; Ceccherini-Silberstein F; Douglas MW; Dore GJ; Harrington P; Lloyd AR; Jacka B; Matthews GV; Wang GP; Pawlotsky J-M; Feld JJ; Schinkel J; Garcia F; Lennerstrand J; Applegate TL, 2017, 'Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S323 - S323, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30970-4

Kwon AJ; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Razavi H; Gray RT, 2017, 'O12 Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued', in Journal of Virus Eradication, Elsevier BV, Vol. 3, pp. 5 - 5, http://dx.doi.org/10.1016/s2055-6640(20)30895-5

Dore G; Grebely J; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng C-Y; Conway B; Iser DM; Huang H-C; Gendrano IN; Kelly MM; Hwang P; Robertson M; Wahl J; Barr E; Platt HL, 2016, 'HCV reinfection and injecting risk behavior following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR Three Year Follow-up Study', in HEPATOLOGY, WILEY, MA, Boston, Vol. 64, pp. 431A - 431A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016

Larney S; Grebely J; Degenhardt L; Amin J; Law M; Alavi M; Dore GJ; Law M, 2016, 'EXPOSURE TO OPIOID SUBSTITUTION THERAPY FOLLOWING HEPATITIS C NOTIFICATION: IMPLICATIONS FOR PROVISION OF ANTIVIRAL THERAPIES IN DRUG TREATMENT SETTINGS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 35, pp. 48 - 48

Grebely J; Mauss S; Brown A; Bronowicki J-P; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ, 2016, 'SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION RECEIVING OPIOID SUBSTITUTION THERAPY: PHASE 3 ION TRAILS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 35, pp. 40 - 41

Alavi M; Janjua N; Yu A; Grebely J; Aspinall E; Innes H; Valerio H; Hayes P; Krajden M; Amin J; Law M; George J; Goldberg D; Hutchinson S; Dore G, 2016, 'DOES ALCOHOL DEPENDENCY EXPLAIN DIFFERENCES IN RATES OF DECOMPENSATED CIRRHOSIS AMONG PEOPLE WITH A HEPATITIS C NOTIFICATION? AN INTERNATIONAL COMPARISON', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, Vol. 64, pp. S462 - S463, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)00776-5

Martinello M; Petoumenos K; Grebely J; Gane E; Hellard M; Shaw D; Sasdeusz J; Applegate T; Lamoury F; Yeung B; Maire L; Dore G; Matthews G, 2016, 'INCIDENCE OF HCV REINFECTION AMONG TREATED INDIVIDUALS WITH RECENTLY ACQUIRED INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, Vol. 64, pp. S620 - S621, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01152-1

Grebely J; Marshall AD; Krahe M; Erratt A; Telenta J; Treloar C; Jones SC; Adey S; Bath N; How-Chow D; Byrne J; Harvey P; Dunlop AJ; Applegate TL; Lamoury F; Mowat Y; Jauncey M; Read P; Gilliver R; Smith J; Collie T; Dore GJ, 2016, 'A LIVER HEALTH PROMOTION INTERVENTION INTEGRATING NON-INVASIVE LIVER DISEASE SCREENING IN DRUG AND ALCOHOL SETTINGS: THE LIVERLIFE STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 35, pp. 40 - 40

Zeuzem S; Mizokami M; Pianko S; Mangia A; Han K-H; Martin R; Svarovskaia ES; Dvory-Sobol H; Doehle B; Pang PS; Knox SJ; McHutchison JG; Brainard DM; Miller MD; Mo H; Chuang W-L; Jacobson IM; Dore G; Sulkowski MS, 2015, 'Prevalence of Pre-Treatment NS5A Resistance Associated Variants in Genotype 1 Patients Across Different Regions Using Deep Sequencing and Effect on Treatment Outcome with LDV/SOF', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, Vol. 62, pp. 254A - 255A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015

Conway B; Luo Y; Arama V; Ghesquiere W; Sasadeusz J; Skoien R; Soza A; Inglot M; Sullivan D; Podsadecki T; Dore G, 2015, 'Ombitasvir/Paritaprevir/r and Dasabuvir plus /- Ribavirin is Better Tolerated Than Telaprevir plus Peginterferon/Ribavirin With Less Frequent and Less Severe Anemia in the MALACHITE-I and MALACHITE-II Trials', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, Vol. 62, pp. 782A - 783A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015

Janjua NZ; Yu A; Kuo ME; Alavi M; Woods R; Alvarez M; Dore G; Tyndall M; Krajden M, 2015, 'Timing of Hepatitis B and C Diagnosis Relative to Hepatocellular Carcinoma Diagnosis in the BC Hepatitis Testers Cohort (BC-HTC)', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, Vol. 62, pp. 480A - 480A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015

Alavi M; Grebely J; Micallef M; Dunlop A; Balcomb A; Day C; Treloar C; Bath N; Haber P; Dore G, 2015, 'P0883 : Treatment for hepatitis C virus infection among people who inject drugs in the opioid substitution setting: The ethos study', in Journal of Hepatology, Elsevier, AUSTRIA, Vienna, Vol. 62, pp. s673, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 22 April 2015 - 26 April 2015, http://dx.doi.org/10.1016/s0168-8278(15)31085-0

Dore GJ, 2013, 'MOVING THE AGENDA FORWARD: ENHANCING HCV TREATMENT UPTAKE AND OUTCOMES FOR PEOPLE WITH DRUG DEPENDENCY', in DRUG AND ALCOHOL REVIEW, WILEY-BLACKWELL, Vol. 32, pp. 2 - 3

Eslam M; Leung R; Berg T; Irving WL; Mangia A; Sheridan D; Abate ML; Weltman M; Spengler U; Mollison L; Cheng W; Dore GJ; Powell E; Riordan S; Douglas M; Suppiah V; Stewart GJ; Booth DR; George J; Ahlenstiel G, 2013, 'Association of IFNL3 polymorphisms with fibrosis progression in viral and non-viral chronic liver disease', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, Vol. 28, pp. 67 - 67

Micallef JM; Jauncey M; Amin J; Rawlinson W; Gilmour S; van Beek I; Kaldor JM; White PA; Dore GJ, 2003, 'Hepatitis C virus reinfection within a cohort of injecting drug users.', in HEPATOLOGY, W B SAUNDERS CO, MASSACHUSETTS, BOSTON, Vol. 38, pp. 266A - 266A, presented at 54th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease, MASSACHUSETTS, BOSTON, 24 October 2003 - 28 October 2003, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000185816700230&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Reports

Wilkinson A; Griffin S; Hellard M; Stoové M; Dore G; Grebely J; Pedrana A; Doyle J; Thompson A; Hajarizadeh B; Aitken C; Broady T; Combo T, 2023, Australia’s progress towards hepatitis C elimination: Annual Report 2023, http://dx.doi.org/10.26190/4d4f-5n41

Hajarizadeh B; Carson J; Dore G, 2023, Monitoring hepatitis C treatment uptake in Australia: Issue #13, July 2023, The Kirby Institute, UNSW, Sydney, Australia, http://dx.doi.org/10.26190/81wp-fr56, https://www.kirby.unsw.edu.au/research/reports/monitoring-hepatitis-c-treatment-uptake-australia-issue-13-july-2023

Wilkinson A; Hayes M; Hellard M; Stoové M; Dore G; Grebely J; Pedrana A; Doyle J; Thompson A; Hajarizadeh B; Alavi M; Aitken C; Broady T; Combo T, 2022, Australia's progress towards hepatitis C elimination: annual report 2022, http://dx.doi.org/10.26190/ge22-aq55

Bajis S; Dore G; Alavi M; McGregor S; Kwon A; Monaghan R; Iversen J; Martinello M; Buckland G; Guy R; Kaldor J; Grebely J, 2021, Progress towards hepatitis C elimination among Aboriginal and Torres Strait Islander people in Australia: monitoring and evaluation report, The Kirby Institute, UNSW Sydney, Sydney, Australia, https://kirby.unsw.edu.au/report/progress-towards-hepatitis-c-elimination-among-aboriginal-and-torres-strait-islander-people

Alavi M; Valerio H; Selvey C; Dore G, 2019, Hepatitis C Elimination in NSW: Monitoring Evaluation Report 2019, https://kirby.unsw.edu.au/report/hepatitis-c-elimination-nsw-monitoring-and-evaluation-report-2019

Kwon J; Gray R; Dore G; Grebely J; Guy R; Hajarizadeh B; Cunningham E, 2017, 2017 Estimates and Projections of the Hepatitis C Virus Epidemic in NSW: Summary Report, Sydney: Kirby Institute, UNSW Sydney

Wilson D; Kwon A; Anderson J; Thein H; Law M; Maher L; Dore G; Kaldor J, 2009, Return on investment 2: evaluating the cost-effectiveness of needle and syringe programs among injecting drug users in Australia, Publications Production Unit (Public Affairs, Parliamentary and Access Branch) Commonwealth Department of Health and Ageing, Canberra, Australia, 3123, http://www.nchecr.unsw.edu.au/nchecrweb.nsf/resources/Reports/$file/RO-2ReportLQ.pdf

Thein H-H; Maher L; Dore G, 2004, Australian NSP Survey National Data Report 1999-2003, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney

Theses / Dissertations

Hosseini Hooshyar S; Matthews G; Dore G; Martinello M, 2022, Hepatitis C elimination among people living with HIV, http://dx.doi.org/10.26190/unsworks/24455

Bartlett SR, 2017, Molecular epidemiology of recently acquired hepatitis C virus infection in Australia

Preprints

Young C; Singh M; Jackson KJL; Field MA; Peters TJ; Angioletti-Uberti S; Frenkel D; Ravishankar S; Gupta M; Wang JJ; Agapiou D; Faulks ML; Al-Eryani G; Luciani F; Gordon TP; Reed JH; Danta M; Carr A; Kelleher AD; Dore GJ; Matthews G; Brink R; Bull RA; Suan D; Goodnow CC, 2024, Self-reactive B cells traverse a perfect storm of somatic mutagenesis to cause a virus-induced autoimmune disease, http://dx.doi.org/10.1101/2024.01.07.574561

Joseph Yeoh YK; Dore GJ; Lockart I; Danta M; Flynn C; Blackmore C; Levy MT; George J; Alavi M; Hajarizadeh B, 2023, Temporal change in etiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients with hepatocellular carcinoma in New South Wales, Australia, http://dx.doi.org/10.1101/2023.02.20.23286164

Phetsouphanh C; Jacka B; Ballouz S; Jackson KJL; Wilson D; Manandhar B; Klemm V; Tan H-X; Wheatley A; Aggarwal A; Akerman A; Milogiannakis V; Starr M; Cunningham P; Turville S; Kent S; Byrne A; Brew B; Darley D; Dore G; Kelleher A; Matthews G, 2023, Improvement of immune dysregulation and health-related quality of life in individuals with long COVID at 24-months following SARS-CoV-2 infection, http://dx.doi.org/10.1101/2023.08.27.23294704

Phetsouphanh C; Khoo WH; Jackson K; Klemm V; Howe A; Aggarwal A; Akerman A; Milogiannakis V; Stella AO; Rouet R; Schofield P; Faulks M; Law H; Danwilai T; Starr M; Munier ML; Christ D; Singh M; Croucher P; Brilot-Turville F; Turville S; Phan TG; Dore G; Darley D; Cunningham P; Matthews G; Kelleher A; Zaunders J, 2022, High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells, http://dx.doi.org/10.1101/2022.07.22.22277947

Cysique L; Jakabek D; Bracken S; Allen-Davidian Y; Heng B; Chow S; Dehhaghi M; Pires AS; Darley D; Byrne A; Phetsouphanh C; Kelleher A; Dore G; Matthews G; Guillemin G; Brew B, 2022, Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: a longitudinal observational study, http://dx.doi.org/10.1101/2022.06.07.22276020

Kwon J; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT, Australia on Track to Achieve Who HCV Elimination Targets Following Rapid Initial DAA Treatment Uptake: A Modelling Study, http://dx.doi.org/10.2139/ssrn.3213670

Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua N; fierer D; Chromy D; Rockstroh JK; Martin T; Ingiliz P; Hung C-C; Dore GJ; Martinello M; Matthews G, Hepatitis C Reinfection Risk Following Successful Therapy Among People Living with HIV: A Global Systematic Review, Meta-Analysis, and Meta-Regression, http://dx.doi.org/10.2139/ssrn.3958916

Koopsen J; Matthews G; Rockstroh JK; Applegate TL; Bhagani SR; Grebely J; Rauch A; Sacks-Davis R; Ingiliz P; Boesecke C; Rebers S; Feld J; Bruneau J; Martinello M; Hellard ME; Dore GJ; Schinkel J; van der Valk M; Study Group REACT, Hepatitis C Virus Transmission Dynamics in a Global Cohort of Men Who Have Sex with Men with Recently Acquired Infection, http://dx.doi.org/10.2139/ssrn.4125248

Lockhart I; Yeo MGH; Hajarizadeh B; Dore GJ; Danta M, Hepatocellular Carcinoma Incidence After Hepatitis C Cure Among Patients With Advanced Fibrosis or Cirrhosis: A Systematic Review and Meta-Analysis, http://dx.doi.org/10.2139/ssrn.3950271

Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Rowling D; Doong N; Jackson E; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV, Moving Towards HCV Elimination Among People Living with HIV in Australia: Analysis of the CEASE Prospective Cohort Study, http://dx.doi.org/10.2139/ssrn.3269607

Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon J; Lloyd AR; Dore GJ; Wiseman V; Grebely J, Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis, http://dx.doi.org/10.2139/ssrn.4267510

Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon J; Lloyd AR; Dore GJ; Wiseman V; Grebely J, Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis, http://dx.doi.org/10.2139/ssrn.4267527

Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ; Group S-CS, Reduced Hepatitis C Incidence Associated with Rapid Treatment Scale-Up in Australian Prisons: Treatment-as-Prevention in the SToP-C Study, http://dx.doi.org/10.2139/ssrn.3709824

Joseph S; Dore GJ, Vaccine Apartheid: A Human Rights Analysis of COVID-19 Vaccine Inequity, http://dx.doi.org/10.2139/ssrn.3876848

Other

Dore GJ; Grebely J, 2017, Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030, Elsevier, http://dx.doi.org/10.1016/j.jhep.2017.03.035

Grebely J; Swan T; Hickman M; Bruneau J; Bruggmann P; Dalgard O; Litwin A; Backmund M; Dore GJ, 2017, Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C, Elsevier, http://dx.doi.org/10.1016/j.jhep.2016.12.028

Back to profile page